[1] Jahnke MN.Vascular Lesions.Pediatr Ann. 2016;45(8):e299–305
[2] Sadick M, Müller-Wille R, Wildgruber M, Wohlgemuth WA.Vascular Anomalies (Part I): Classification and Diagnostics of Vascular Anomalies.Rofo. 2018;190(9):825–835.
[3] Kilcline C, Frieden IJ. Infantile hemangiomas: how common are they? A systematic review of the medical literature.PediatrDermatol, 2008; 25(2): 168–173.
[4] Léauté-Labrèze C, Harper JI, Hoeger PH.Infantile haemangioma.Lancet. 2017;390(10089):85–94.
[5] McCuaig CC.Update on classification and diagnosis of vascular malformations.CurrOpinPediatr. 2017;29(4):448–454.
[6] Chinnadurai S, Sathe NA, Surawicz T.Laser treatment of infantile hemangioma: A systematic review.Lasers Surg Med. 2016;48(3):221–233.
[7] Darrow DH, Greene AK,Mancini AJ. Diagnosis and Management of Infantile Hemangioma: Executive Summary. Pediatrics, 2015; 136(4): 786–791.
[8]Léauté-Labrèze C, Dumas de la Roque E, Hubiche T. Propranolol for severe hemangiomas of infancy. N Engl J Med, 2008; 358(24):2649–2651.
[9]Price A, Rai S, Mcleod RWJ, Birchall JC, Elhassan HA.Topical propranolol for infantile haemangiomas: a systematic review.J EurAcadDermatolVenereol. 2018;32(12):2083–2089.
[10] Prey S, Voisard JJ, Delarue A, Lebbe G, Taïeb A, Léauté-Labrèze C, Ezzedine K. Safety of Propranolol Therapy for Severe Infantile Hemangioma.JAMA. 2016; 315(4):413–415.
[11]Bayart CB, Tamburro JE, Vidimos AT, Wang L, Golden AB.Atenolol Versus Propranolol for Treatment of Infantile Hemangiomas During the Proliferative Phase: A Retrospective Noninferiority Study.PediatrDermatol. 2017;34(4):413–421.
[12] Khan M, Boyce A, Prieto-Merino D, Svensson Å, Wedgeworth E, Flohr C.The Role of Topical Timolol in the Treatment of Infantile Hemangiomas: A Systematic Review and Meta-analysis.ActaDermVenereol. 2017;97(10):1167–1171.
[13] Ran Y, Chen S, Dai Y, Kang D, Lama J, Ran X, Zhuang K.Successful treatment of oral itraconazole for infantile hemangiomas: a case series.J Dermatol. 2015;42(2):202–206.
[14] Triana P, Dore M, Cerezo VN, Cervantes M, Sánchez AV, Ferrero MM, González MD, Lopez-Gutierrez JC.Sirolimus in the Treatment of Vascular Anomalies.Eur J Pediatr Surg. 2017;27(1):86–90.
[15]Swetman GL, Berk DR, Vasanawala SS, Feinstein JA, Lane AT, Bruckner AL.Sildenafil for severe lymphatic malformations.N Engl J Med. 2012;366(4):384–386.
[16]Horbach SE, Jolink F, van der Horst CM.Oral sildenafil as a treatment option for lymphatic malformations in PIK3CA-related tissue overgrowth syndromes.DermatolTher. 2016;29(6):466–469.
[17] Hatok J, Babusikova E, Matakova T, Mistuna D, Dobrota D, Racay P.In vitro assays for the evaluation of drug resistance in tumor cells.ClinExp Med. 2009;9(1):1–7.
[18]Bauer JH, Pape B, Zajicek J, Groshong T.Propranolol in human plasma and breast milk.Am J Cardiol. 1979; 43(4):860–862.
[19]Tejani A, Alexander S, Ettenger R, Lerner G, Zimmerman J, Kohaut E, Briscoe DM.Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis.Pediatr Transplant. 2004; 8(2):151–160.
[20] Cree IA, Kurbacher CM, Untch M, et al. Correlation of clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anticancer Drugs. 1996;7:630–635.
[21] Neubauer H, Stefanova M, Solomayer E, et al. Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer. Anticancer Res. 2008;28:949–955.
[22]Morgan MM, Johnson BP, Livingston MK, Schuler LA, Alarid ET, Sung KE, Beebe DJ.Personalized in vitro cancer models to predict therapeutic response: Challenges and a framework for improvement.PharmacolTher. 2016;165:79–92.
[23] Van Ingen J, Kuijper EJ.Drug susceptibility testing of nontuberculous mycobacteria.Future Microbiol. 2014;9(9):1095–1110.
[24]Zhang J, Li H.Heterogeneity of tumor chemosensitivity in ovarian epithelial cancer revealed using the adenosine triphosphate-tumor chemosensitivity assay.Oncol Lett. 2015;9(5):2374–2380.
[25]Smith CJF, Friedlander SF, Guma M, Kavanaugh A, Chambers CD.Infantile Hemangiomas: An Updated Review on Risk Factors, Pathogenesis, and Treatment.Birth Defects Res. 2017;109(11):809–815.
[26]Choi CH, Ryu JY, Cho YJ, Jeon HK, Choi JJ, Ylaya K, Lee YY, Kim TJ, Chung JY, Hewitt SM, Kim BG, Bae DS, Lee JW. The anti-cancer effects of itraconazole in epithelial ovarian cancer.Sci Rep. 2017;7(1):6552.
[27] Goss JA, Konczyk DJ, Alomari MH, Maclellan RA, Greene AK.Propranolol Treatment of Vascular Anomalies Other Than Infantile Hemangioma.J Craniofac Surg. 2017;28(8):2001–2003.
[28] Phillips JD, Zhang H, Wei T, Richter GT.Expression of β-Adrenergic Receptor Subtypes in Proliferative, Involuted, and Propranolol-Responsive Infantile Hemangiomas.JAMA Facial Plast Surg. 2017;19(2):102–107.
[29] Rankin H, Zwicker K, Trenor CC 3rd. Caution is recommended prior to sildenafil use in vascular anomalies.Pediatr Blood Cancer. 2015, 62(11):2015–2017.